Budapest, Hungary; Cambridge, MA & Richmond, VA (PRWEB) September 24, 2014 – Omixon collaborates with G3 and Genomics England to HLA genotype 340 individuals by three different methods in a bit to demonstrate equivalency among WGS approaches, best in class targeted approaches (Holotype HLA) and legacy methods (Sanger SBT).
Read the full article here:
News